TNDM - Tandem Diabetes Care, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
36.75
-1.84 (-4.77%)
As of 1:57PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close38.59
Open38.99
Bid37.31 x 800
Ask37.40 x 1200
Day's Range36.54 - 39.50
52 Week Range2.14 - 52.55
Volume1,123,696
Avg. Volume3,471,718
Market Cap2.103B
Beta (3Y Monthly)-0.85
PE Ratio (TTM)N/A
EPS (TTM)-5.10
Earnings DateNov 1, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.50
Trade prices are not sourced from all markets
  • Most Analysts Are Bullish on Tandem Stock
    Market Realist6 hours ago

    Most Analysts Are Bullish on Tandem Stock

    Seven of the total ten analysts covering Tandem Diabetes Care (TNDM) in October 2018 have given Tandem a “buy” or higher rating, and three analysts have given Tandem a “hold” rating. The mean rating for Tandem is 2.1 with a target price of $52.5, which implies an upside potential of 36.7% over Tandem’s trading price of $38.40 on October 17.

  • What Can We Expect from Tandem’s Bottom Line in Third Quarter?
    Market Realistyesterday

    What Can We Expect from Tandem’s Bottom Line in Third Quarter?

    Tandem Diabetes Care (TNDM) is expected to incur a net loss of $18.22 million in the third quarter of 2018. Its net loss was $16.03 million in the year-ago period, which translates into a net loss per share of $0.33 for the third quarter of fiscal 2018 as compared with a net loss per share of $3.09 for the third quarter of fiscal 2017. On October 12, Tandem announced that its t:slim X2 insulin pump received approval in Canada and is the only continuous glucose monitoring (or CGM) integrated insulin pump approved in the country.

  • Tandem Diabetes (TNDM) Q3 Earnings Preview: What to Look Out For
    Zacksyesterday

    Tandem Diabetes (TNDM) Q3 Earnings Preview: What to Look Out For

    Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What to Expect from Tandem Diabetes Care’s Third-Quarter Earnings
    Market Realistyesterday

    What to Expect from Tandem Diabetes Care’s Third-Quarter Earnings

    Tandem Diabetes Care (TNDM) is expected to report its third-quarter of fiscal 2018 earnings on November 1. In this series, we’ll take a look at Tandem’s expected top line, operational, and bottom-line performance for the third quarter of 2018, analysts’ recommendations, and the performance of Tandem stock so far this year.

  • Business Wire2 days ago

    Tandem Diabetes Care to Announce Third Quarter 2018 Financial Results on November 1, 2018

    Tandem Diabetes Care®, Inc. , a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, plans to release its third quarter 2018 results after the financial markets close on Thursday, November 1, 2018.

  • Business Wire7 days ago

    Tandem Diabetes Care Receives Health Canada Approval to Market t:slim X2 Insulin Pump

    Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced that it has received a Heath Canada Medical Device License for the t:slim X2™ Insulin Pump. The t:slim X2 Pump features Dexcom G5® Mobile CGM integration,1 making it the only CGM-integrated insulin pump approved in Canada for making daily diabetes treatment decisions without fingersticks.2 The Company plans to launch the t:slim X2 Insulin Pump on a province-by-province basis throughout the fourth quarter of 2018 pending the completion of pre-launch activities, including product registration with provincial health programs.

  • 5 Healthcare Stocks to Buy for Complete Portfolio Wellness
    InvestorPlace9 days ago

    5 Healthcare Stocks to Buy for Complete Portfolio Wellness

    Figuring out which healthcare stocks to buy has never been an easy task. President Trump has repeatedly blasted the Affordable Care Act, promising to overhaul our healthcare system. Naturally, many healthcare stocks have experienced a tumultuous ride in the markets under the Trump White House.

  • Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
    Zacks11 days ago

    Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

    Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets bode well for Tandem Diabetes (TNDM).

  • ACCESSWIRE11 days ago

    Today's Research Reports on Trending Tickers: Akcea Therapeutics and Tandem Diabetes Care

    NEW YORK, NY / ACCESSWIRE / October 8, 2018 / U.S. equities plunged on Friday as concerns over rising interest rates countered upbeat economic data. U.S. unemployment rate dropped to 3.7 percent, its lowest ...

  • Implied Volatility Surging for Tandem Diabetes Care (TNDM) Stock Options
    Zacks14 days ago

    Implied Volatility Surging for Tandem Diabetes Care (TNDM) Stock Options

    Tandem Diabetes Care (TNDM) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Is Tandem Diabetes Care (TNDM) Stock Outpacing Its Medical Peers This Year?
    Zacks15 days ago

    Is Tandem Diabetes Care (TNDM) Stock Outpacing Its Medical Peers This Year?

    Is (TNDM) Outperforming Other Medical Stocks This Year?

  • How’s Tandem Diabetes Care Positioned in September?
    Market Realist23 days ago

    How’s Tandem Diabetes Care Positioned in September?

    In August, Tandem Diabetes Care (TNDM) commercially launched the t:slim X2 Insulin Pump with Basal-IQ technology, which has the predictive low glucose suspend feature that helps decrease the frequency and duration of hypoglycemia. Tandem’s t:slim X2 Insulin Pump is combined with the Dexcom G6 CGM System so that no fingersticks are required for calibration.

  • Tandem Diabetes Care (TNDM) Catches Eye: Stock Jumps 7.4%
    Zacks23 days ago

    Tandem Diabetes Care (TNDM) Catches Eye: Stock Jumps 7.4%

    Tandem Diabetes Care (TNDM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Why TNDM’s Stock Price Rose 7.4% on September 25
    Market Realist23 days ago

    Why TNDM’s Stock Price Rose 7.4% on September 25

    On September 25, Tandem Diabetes Care’s (TNDM) stock price closed at $47.84, which represents ~7.43% growth from the close of $44.53 on September 24. On September 20, Tandem Diabetes Care’s stock price grew 8.09% to 43.18 from the close of $39.95 on September 19.

  • Business Wire24 days ago

    Tandem Diabetes Care Increases 2018 Sales Guidance and Provides Estimated Third Quarter Sales Results

    Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that it has increased its 2018 sales guidance to $150 million to $158 million, from $140 million to $148 million, following continued strong domestic sales in the third quarter and the recent launch of the t:slim X2™ Insulin Pump in select international markets. Sales, training and customer service outside of the United States are being provided by regional distribution partners, except in Canada. The t:slim X2 Insulin Pump is currently under review by Health Canada.

  • Options Traders Expect Huge Moves in Tandem Diabetes Care (TNDM) Stock
    Zackslast month

    Options Traders Expect Huge Moves in Tandem Diabetes Care (TNDM) Stock

    Tandem Diabetes Care (TNDM) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Motley Foollast month

    Why Nio, Mersana Therapeutics, and Tandem Diabetes Care Slumped Today

    Find out what took the energy out of these stocks.

  • Why Tandem Diabetes Care Stock Is Crashing Today
    Market Realistlast month

    Why Tandem Diabetes Care Stock Is Crashing Today

    Today, Tandem Diabetes Care (TNDM) stock continued the declining trend it began on September 14. Baird downgraded the stock recommendation from “buy” to “neutral.” On September 14, TNDM stock registered a decline of ~6.7% in pre-market trading and the stock was down ~7% during the day. None of the analysts recommend a “buy” for Tandem Diabetes Care.

  • Motley Foollast month

    Why Tandem Diabetes Care Is Sinking Today

    Shares dropped by double digits on Monday. What's going on?

  • Benzingalast month

    Once Again, Baird Predicts End To Tandem's 'Fantastic' Run

    Without pause, Tandem Diabetes Care Inc (NASDAQ: TNDM ) has surged 1,915 percent year-to-date. One sell-side analyst said Friday that the medical device manufacturer's valuation has peaked.  The Rating ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: InspireMD and Tandem Diabetes Care

    NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent ...

  • Business Wirelast month

    Tandem Diabetes Care to Webcast Investor & Analyst Day on September 25, 2018

    Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced it will host an Institutional Investor and Analyst Day from 8:30am to 1:00pm Pacific Time on Tuesday, September 25, 2018 in San Diego, California. The program will include presentations regarding the Company’s longer-term vision, product pipeline, and international expansion. In addition, presentations will be given by clinical and industry experts on the subject of automated insulin delivery (AID).

  • Tandem Diabetes Is Firing on All Cylinders
    InvestorPlacelast month

    Tandem Diabetes Is Firing on All Cylinders

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM) continues to float higher, even without any major news. The market easily absorbed the company’s $100 million equity offering which was underwritten in August 2018. Not only are those who bought that offering at $28.50 in the green, but longtime investors in TNDM stock believe that sales of Tandem’s new insulin pump in the United States will justify the stock’s strong run-up.Source: Apple

  • Tandem Diabetes Care: One of the Best Medtech Stocks in 2018
    Market Realistlast month

    Tandem Diabetes Care: One of the Best Medtech Stocks in 2018

    Tandem Diabetes Care (TNDM) has been one of the best-performing medical device companies in 2018 and has already reported a YoY (year-over-year) rise of 1,814.4% YTD (year-to-date). To know more about Tandem Diabetes Care, be sure to read Tandem Diabetes Care Continues Its Strong Performance in Q2 2018. On June 21, the FDA approved Tandem Diabetes Care’s t:slim X2 insulin pump with Basal-IQ technology, an automated insulin delivery system that can help reduce the frequency of hypoglycemic events in diabetes patients.